Big-3 Specialty Pharmacy: CVS Specialty vs Accredo vs OptumRx Specialty
Head-to-head comparison of the three PBM-owned specialty pharmacies that collectively dispense ~66% of U.S. specialty drug revenue.
Curated by Rx Almanac using company materials, public reporting, and editorial synthesis.
On this page
Save this comparison — email yourself the full breakdown.
Join 200+ biotech launch teams on the weekly digest.
Market Position Summary
The Big-3 collectively control 66% of U.S. specialty pharmacy dispensing revenue ($265B 2024 market), and pharmacies affiliated with the Big-3 PBMs received 68% of specialty dispensing revenue in 2023 (up from 54% in 2016). For most national-launch specialty drugs, biotech sponsors will engage at least one — and often all three — of these vendors as part of a multi-source LDD strategy. (Source: Drug Channels: Top 15 US Pharmacies of 2025, accessed 2026-04-17)
| Attribute | CVS Specialty | Accredo (Evernorth) | OptumRx Specialty |
|---|---|---|---|
| Parent Company | CVS Health (NYSE: CVS) | Cigna Group (NYSE: CI) via Evernorth | UnitedHealth Group (NYSE: UNH) via Optum |
| PBM Sister | CVS Caremark | Express Scripts | OptumRx |
| PBM-Affiliated Volume | Caremark-affiliated book | Express Scripts-affiliated book | OptumRx / UnitedHealthcare-affiliated book |
| 2024 Dispensing Revenue (est.) | ~$75–80B | ~$59.5B | ~$40–55B |
| Market Share | ~28–30% | ~22–26% | ~17–21% |
| Rank | #1 | #2 | #3 |
| Specialty Drug Coverage | Broad LDD and specialty-drug coverage | Broad therapeutic coverage | Broad specialty formulary coverage |
| Physical Access | CVS retail / Specialty Connect adjacency | Primarily mail and specialty fulfillment | Primarily mail and specialty fulfillment¹ |
| Home Infusion Sister | Coram (specialty biologics / TPN / enteral focus after Oct 2024 restructuring; Option Care now leads by revenue) | CuraScript SD (provider-direct distribution) | Optum Infusion Pharmacy (smaller) |
| CGT Capability | Cell & Gene Therapy Experience Center, Fairfield NJ | GeneAXS dedicated team | Embedded in OptumRx Specialty (no branded sub-team) |
| Care Mgmt Adjacency | Accordant Health Services (20 rare conditions) | None equivalent | Optum Health (3,000+ provider locations) |
| Health-System SP Exposure | Limited (CVS Caremark contracts) | Shields ($3.5B preferred equity) + CarePathRx (acquired 2026) | None at scale |
¹ OptumRx operates 435+ Genoa Healthcare community/behavioral pharmacies (acquired 2018, $2.5B), but Genoa is positioned as community/behavioral pharmacy, not traditional specialty pharmacy.
Vertical Integration Stack Comparison
The Big-3 SPs are not standalone businesses — each is a node in a different vertically integrated healthcare conglomerate. Understanding the parent stack matters because it drives (a) captive prescription volume, (b) regulatory exposure, (c) which adjacent products manufacturers can negotiate alongside specialty pharmacy access.
| Layer | CVS Health | Cigna/Evernorth | UnitedHealth/Optum |
|---|---|---|---|
| Insurance / Payer | Aetna (~25M+ members) | Cigna Healthcare | UnitedHealthcare (~50M+ members) |
| PBM | CVS Caremark | Express Scripts | OptumRx |
| Specialty Pharmacy | CVS Specialty (#1) | Accredo (#2) | OptumRx Specialty (#3) |
| Home Infusion | Coram (#1 home infusion) | CuraScript SD (provider-direct) | Optum Infusion |
| Retail Pharmacy | CVS retail / Specialty Connect adjacency | None | Genoa Healthcare behavioral/community pharmacy adjacency |
| Provider Network | Oak Street Health, MinuteClinic, Signify Health | Evernorth Care | Optum Health (3,000+ locations) |
| Data/Analytics | CVS analytics + Cordavis (biosimilars) | Evernorth Health Services | Optum Insight (130M+ lives data) |
| Care Management | Accordant (rare disease) | Therapeutic Resource Center clinical model | Optum Health clinical |
| Total Parent Revenue (2025) | ~$473B gross | $190B+ Cigna group | $439B+ UHG outlook |
| Vertical Integration Depth | Broadest (insurance + PBM + SP + retail + provider + biosimilars) | PBM + SP + Distribution + Provider + new health-system SP exposure | Deepest (insurance + PBM + SP + provider + data — all owned) |
Implication for manufacturers: Negotiating with a Big-3 SP is rarely just an SP negotiation. Manufacturers typically face combined PBM + SP + (sometimes payer) packages where formulary access, rebate terms, and SP designation are interdependent. Independent SPs (PANTHERx Rare, Orsini, BrightSpring) offer a structurally different negotiation — fewer adjacent dependencies, deeper therapeutic intimacy, but smaller captive volume. Shields Health Solutions sits in a separate health-system-SP-accelerator lane (it enables hospital-owned SPs rather than dispensing directly), and its capital stack — Sycamore Partners majority plus $3.5B Evernorth/Cigna preferred equity (both Sep 2025) — means it is not an unaffiliated “independent” in the same sense as PANTHERx, Orsini, or BrightSpring.
Therapeutic Capability Comparison
| Therapy Area | CVS Specialty | Accredo (Evernorth) | OptumRx Specialty |
|---|---|---|---|
| Oncology | Oncology specialty capability, REMS handling, and retail / Specialty Connect adjacency | Oncology TRC model | Broad oncology coverage; less branded clinical model |
| Cell & Gene Therapy | CGT Experience Center (Fairfield NJ) | GeneAXS dedicated team; payer contracting at scale | Standard SP CGT capabilities; no branded CGT sub-team |
| Rare Disease | Rare disease program plus Accordant care-management adjacency | Rare Disease TRC; partnerships with PANTHERx and others for ultra-rare | Standard SP rare disease coverage |
| Multiple Sclerosis | Full DMT formulary | MS TRC (dedicated) | Full DMT formulary |
| Inflammatory/Immunology | TNF/IL-17/IL-23/JAK; broad coverage | Inflammatory TRC (dedicated) | Broad coverage |
| Pulmonary (PAH) | Pharmacist-managed PAH program (Tyvaso adherence: 87% PDC vs 78% control) | Pulmonary TRC | Standard coverage |
| Hemophilia / Bleeding Disorders | Standard coverage | Bleeding Disorders TRC; factor replacement, gene therapy | Standard coverage |
| HIV | Standard coverage; PrEP coordination | HIV TRC (dedicated) | Standard coverage |
| Hepatitis C | Standard coverage | Hepatitis C TRC (dedicated) | Standard coverage |
| Fertility | Limited | Freedom Fertility — one of largest fertility pharmacy programs nationally | Limited |
| Transplant Immunosuppression | Standard coverage | Transplant TRC (dedicated) | Standard coverage |
| Behavioral Health Specialty | Standard | Standard | Strongest via Genoa Healthcare integration (435+ behavioral pharmacies) |
| Total TAs Covered | Broad LDD and specialty-drug coverage | Broad TA coverage through TRC model | Broad specialty-drug coverage |
Therapeutic specialization assessment: Accredo has the deepest branded clinical model with dedicated Therapeutic Resource Centers (TRCs) staffed around disease-specific pharmacist and nurse support. CVS Specialty has broad LDD designation depth and unique retail / Specialty Connect adjacency. OptumRx Specialty has broad formulary coverage and a behavioral-health adjacency via Genoa, but lacks a comparably branded therapeutic specialization model.
Patient Experience & Clinical Outcomes
Published outcomes data is uneven across the Big-3. CVS and Accredo publish more detailed patient-experience and adherence data than OptumRx Specialty, where specialty pharmacy outcomes are less separately reported.
| Metric | CVS Specialty | Accredo (Evernorth) | OptumRx Specialty |
|---|---|---|---|
| First-Call Resolution | Not separately disclosed | Not independently benchmarked in public sources | Not separately disclosed |
| Patient Satisfaction Score | Vendor-published patient-experience materials exist | Vendor-published patient-experience materials exist | Not separately disclosed |
| Adherence / MPR Evidence | Vendor-published Specialty Connect and disease-program materials exist | Vendor-published clinical model materials exist | Not separately disclosed |
| Mobile App Adoption | Active (CVS Specialty mobile app) | Active patient digital tools | Active (OptumRx digital platform) |
| Prescriber Portal Adoption | CVS Specialty Central | MyAccredoPatients.com | OptumRx prescriber portal |
| Cold-Chain Accuracy | Standard SP cold chain | Cold-chain process marketed | Standard SP cold chain |
| PAH Adherence Evidence | Vendor-published PAH program materials exist | Not directly comparable | Not separately disclosed |
| Oncology Outcomes Evidence | Not separately disclosed | Vendor-published oncology outcomes materials exist | Not separately disclosed |
| Specialty Connect / Hybrid Model | Mail + retail hybrid model | Not applicable (mail-only) | Not applicable (mail-only) |
Outcomes assessment: Both CVS Specialty and Accredo publish clinical outcomes data that supports their commercial positioning, but much of the precision is vendor-published and should be validated in RFP diligence. OptumRx Specialty publishes less granular specialty-pharmacy outcomes data, instead emphasizing its position within the Optum data and analytics platform.
Recent Regulatory & M&A Developments (2024–2026)
The Big-3 SPs all face overlapping but distinct regulatory pressures and M&A activity. The cumulative effect of (a) FTC PBM enforcement, (b) state PBM-pharmacy divestiture laws (Arkansas effective Jan 2026), (c) Consolidated Appropriations Act 2026 spread-pricing ban, and (d) the Patients Before Monopolies Act would, if fully implemented, structurally separate PBM and pharmacy operations across all three vendors.
| Event | CVS Specialty / CVS Health | Accredo / Evernorth / Cigna | OptumRx / UnitedHealth |
|---|---|---|---|
| FTC PBM Enforcement | March 2026 insulin consent agreement (no penalty) | February 2026 FTC consent order (spread pricing elimination, formulary transparency) | DOJ antitrust scrutiny ongoing; no consent order yet |
| CEO Transition | Oct 2024: David Joyner replaced Karen Lynch (PBM-first orientation) | July 2025: Brian Evanko replaced David Cordani | Stable: Andrew Witty (UHG CEO) |
| Major Acquisition Activity | Aetna/Signify/Oak Street ($60B+ debt) — Oct 2025 Oak Street closures (16 locations) | February 2026: CarePathRx acquisition closed (wholly-owned Evernorth subsidiary); Sept 2025: Shields $3.5B preferred equity | 2018: Genoa $2.5B; 2019: Diplomat combination |
| Specialty Channel Revenue Growth | $70.9B (FY2024) → $79.3B (FY2025), +11.9% YoY | Specialty meds grew 280% over past two decades; Newark facility opened Oct 2025 (200K sq ft) | $154.7B total OptumRx (2025), +16% YoY (specialty not separately reported) |
| PBM Share Movement | 34% → 27% (2023 → 2024); lost Centene (20M lives) | 23% → 30% (2023 → 2024); won Centene | Stable ~23% |
| Major Litigation | TrueCost adoption (90%+ commercial clients); ongoing PBM reform exposure | January 2026 plaintiff class action (potentially tens of millions of customers) | DOJ antitrust + Optum Health Medicare fraud allegations |
| Health-System SP Strategy | Limited direct exposure | Shields + CarePathRx (now most exposed Big-3 to health-system SP channel) | None at scale |
Regulatory risk assessment: All three vendors face existential risk from PBM-pharmacy structural separation legislation. Of the three, Cigna/Evernorth has the most concentrated PBM/SP structural risk (FTC consent order + class action lawsuit + Patients Before Monopolies Act exposure). CVS Health has the most diversified exposure (broader business including Aetna insurance, retail, providers — pharmacy services share of total smaller). UnitedHealth has the deepest vertical integration (most adjacent businesses to absorb pharmacy services regulatory shock) but also the most overall regulatory scrutiny (DOJ + Optum Health fraud allegations).
Pricing & Commercial Terms (Manufacturer-Facing)
Specialty pharmacy commercial terms are not publicly disclosed but follow general patterns based on the vendor’s vertical position:
| Pricing Dimension | CVS Specialty | Accredo (Evernorth) | OptumRx Specialty |
|---|---|---|---|
| Dispensing Fees | Premium tier (largest scale, walk-in network) | Premium tier (PBM channel value, TRC clinical depth) | Premium tier (broadest captive lives) |
| LDD Designation Costs | Manufacturer pays for inclusion; CVS premium reflects 200+ LDD network depth | Manufacturer pays for inclusion; Accredo charges for TRC clinical model integration | Manufacturer pays for inclusion |
| Data/Reporting Fees | Premium analytics package (CVS analytics + Cordavis biosimilars team) | Real-time dispense data + clinical outcomes via Express Scripts integration | Optum Insight integration available (130M lives data) |
| Bundled Pricing Opportunities | Caremark formulary + CVS Specialty + Coram (IV companion) + Aetna formulary | Express Scripts formulary + Accredo + CuraScript SD (buy-and-bill) | OptumRx formulary + Optum Specialty + Optum Health provider distribution |
| Hub Service Bundling | CareTeam hub-equivalent (no separate hub vendor required) | TRC patient support equivalent | Standard SP patient support |
| Negotiation Leverage Asymmetry | High — CVS controls multiple manufacturer-relevant assets | Highest among Big-3 — Express Scripts is largest single PBM by lives | High — UHG provides broadest captive volume |
Pricing observation: All three vendors charge premium dispensing and LDD fees vs independent SPs. Manufacturers seeking lower per-script economics should consider PANTHERx Rare (rare-focused), Orsini (CGT-focused), BrightSpring/Onco360 (largest independent), or Shields-powered health-system SPs where 340B and provider economics may apply. The Big-3 are typically the largest single channel but rarely the lowest cost per script.
Best-For Recommendations
For biotech launch teams selecting Big-3 SP partners, the choice depends on therapeutic area, distribution strategy, and manufacturer relationship goals. None of the Big-3 are mutually exclusive — most national specialty launches engage all three plus 1–2 independent specialists.
Choose CVS Specialty as primary when:
- Oncology launch with REMS or LDD strategy: CVS’s 250+ oncology medications, ~24,000 oncology prescribers, walk-in locations near NCI cancer centers, and most CGT LDD launches over 5 years make CVS the default oncology SP.
- Cell/gene therapy launch: CGT Experience Center (Fairfield NJ) provides dedicated infrastructure; particularly valuable for autologous therapies requiring chain-of-custody coordination.
- Need for both self-administered + IV-administered specialty biologics: CVS Specialty + Coram bundle is unique — no other Big-3 SP has a comparable home infusion sister at scale.
- Caremark formulary access is strategically important: Bundling SP designation with Caremark formulary negotiation in a single vendor relationship.
- Physical access matters: CVS is the Big-3 SP with meaningful retail / Specialty Connect adjacency.
- Rare disease care management is desired: Accordant Health Services adjacency (20 rare conditions, 25+ years) provides clinical wraparound competitors lack at scale.
Choose Accredo (Evernorth) as primary when:
- PBM channel depth is the priority: Express Scripts gives Accredo a major PBM-affiliated access channel.
- Therapeutic area requires deep clinical specialization: Accredo’s TRC model provides the deepest branded clinical model among Big-3.
- Fertility pharmacy is core: Freedom Fertility (Accredo’s sub-brand) is one of the largest fertility pharmacy programs nationally — no Big-3 competitor matches this.
- Health-system SP channel exposure is desired: Accredo + Shields Health Solutions ($3.5B preferred equity) + CarePathRx (acquired 2026) gives Evernorth the broadest health-system SP optionality among Big-3.
- TRICARE government population is in scope: Accredo serves military beneficiaries via TRICARE contract (March 2024).
- Buy-and-bill provider-direct distribution is needed: CuraScript SD (Accredo’s sister entity) co-located in Newark, DE provides specialty distribution to physician offices and health systems alongside Accredo’s patient-direct dispensing.
Choose OptumRx Specialty as primary when:
- UnitedHealthcare is a major plan sponsor for the patient population: OptumRx’s parent and external-client book can create meaningful channel access.
- Behavioral health specialty drug is in scope: Genoa Healthcare integration (435+ behavioral/community pharmacies) provides specialty footprint for behavioral health and substance use therapeutic areas competitors lack.
- Optum Insight data analytics integration is strategically valuable: 130M+ lives of clinical and claims data enables sophisticated outcomes-based contracting and population health analytics.
- Vertically integrated provider engagement is needed: Optum Health (3,000+ provider locations including ambulatory surgery centers, physician groups) provides direct provider channel for specialty drug administration.
- Broad therapeutic coverage is the priority: OptumRx Specialty has broad formulary coverage.
Use multiple Big-3 vendors (typical for national launches) when:
- LDD network strategy requires multi-source distribution to maximize patient access
- Manufacturer wants to avoid single-PBM concentration risk
- Different PBM formulary positions across UHC, Cigna, and CVS-Caremark plans require parallel SP designations
- Therapeutic area has mixed mail/retail/walk-in demand requiring CVS’s hybrid model alongside Accredo/OptumRx mail-only scale
Consider independent or health-system SPs instead when:
- Ultra-rare disease (n<500 patients/year) where therapeutic intimacy matters more than scale → PANTHERx Rare, Orsini
- Cell/gene therapy where deep CGT-specific clinical model is required → Orsini (12 CGTs), PANTHERx Rare
- Oncology specialty pharmacy with independent positioning → BrightSpring/Onco360
- Health-system 340B optimization or hospital-owned SP → Shields Health Solutions, CarePathRx
- Retail-network leverage with PBM-independent positioning → Walgreens Specialty Pharmacy (Sycamore Partners-controlled post-2025 take-private LBO; ~$24B revenue) — note Sycamore-controlled status when assessing vendor stability
- Manufacturer wants to avoid PBM-pharmacy structural entanglement → any independent SP
- Lower per-script economics required → most independents charge below Big-3 premium tier
Buyer Checklist: Big-3 SP RFP Questions
For manufacturers issuing RFPs to Big-3 SPs, the following questions surface differentiation that vendor sales decks rarely volunteer:
- Captive PBM Volume: What % of expected patient volume will come from your sister PBM’s captive book vs external client book? How does this change if PBM client retention shifts?
- LDD Network Reciprocity: Will you accept a non-exclusive LDD designation, or do you require exclusivity? What is the dispensing fee delta?
- Walk-In Physical Access (CVS only): For our therapeutic area, what % of CVS Specialty patients use walk-in vs mail? Is walk-in access a meaningful clinical differentiator for us?
- Bundled Coram/CuraScript/Optum Infusion (where applicable): Can we bundle home infusion or buy-and-bill distribution alongside specialty pharmacy in a single contract? What discount applies?
- Therapeutic Specialization Depth: For our therapeutic area, what is your dedicated clinical model? Do you have a TRC equivalent (Accredo) or therapeutic-specific clinical pharmacist team?
- Outcomes Data: What patient-level outcomes data (adherence, MPR, PDC, clinical outcomes) will you provide? Real-time or batch? What is the data-sharing fee?
- Health-System SP Channel Conflict (Accredo specifically): Given your Shields and CarePathRx exposure, how do you manage potential channel conflict if our drug is dispensed through a health-system SP that is Shields-enabled?
- PBM Reform Contingency Planning: If federal or state legislation forces structural separation of PBM and SP, what is your continuity plan for our LDD designation?
- Pricing Transparency: What is your dispensing fee structure? Are spread pricing or rebate retention practices part of our economics?
- Manufacturer-Specific Reporting: What custom dashboards/reports will you provide for our brand team? What is the SLA for issue resolution and exception handling?
Analyst Notes
- The Big-3 are not interchangeable — Despite similar pricing tiers and similar surface-level service offerings, the three vendors are structurally different along every dimension that matters: PBM-affiliated channel composition, physical-access model, CGT branded sub-team (Accredo’s GeneAXS only), behavioral health adjacency (OptumRx via Genoa), health-system SP exposure (Accredo via Shields/CarePathRx), and parent company regulatory exposure profile. Manufacturers running Big-3 selection as a generic “best price” RFP miss the underlying strategic choice.
- Cigna/Evernorth is the most pure-play PBM/SP exposure — Of the three, Cigna’s revenue is most dependent on Express Scripts + Accredo combined. CVS Health and UnitedHealth Group both have large adjacent businesses (CVS retail, Aetna; UHC insurance, Optum Health) that diversify their exposure. If PBM-pharmacy separation legislation passes, Cigna/Evernorth absorbs the most concentrated structural impact.
- CVS Specialty’s physical-access model is the most under-discussed asset — CVS retail / Specialty Connect adjacency gives CVS a physical-access posture that mail-only Big-3 competitors cannot match.
- Accredo’s TRC clinical model is the most defensible therapeutic specialization — Dedicated Therapeutic Resource Centers with disease-specific pharmacists/nurses are the deepest branded clinical model among Big-3. CVS Specialty offers therapeutic-specific clinical pharmacist programs but does not brand them as TRCs. OptumRx Specialty has broad formulary coverage but the least visible therapeutic specialization model.
- OptumRx Specialty’s data integration is the most under-leveraged asset — Optum’s data and analytics stack could be valuable for manufacturers requiring outcomes-based contracting or population health analytics, but OptumRx Specialty has not visibly bundled this into manufacturer-facing offerings as aggressively as it could.
- Genoa is OptumRx’s most differentiated specialty footprint — Genoa gives OptumRx a behavioral-health pharmacy adjacency that CVS and Accredo cannot match. For manufacturers launching specialty drugs in behavioral health, substance use, or behavioral-medical comorbidity, OptumRx Specialty + Genoa is the differentiated channel.
- Multi-source LDD strategy is the norm, not the exception — National specialty launches almost always engage 2–3 of the Big-3 plus 1–2 independent SPs. The selection question is rarely “which one?” but “what is the role of each?” — primary vs secondary, captive PBM vs broad access, scale vs intimacy. Treat the Big-3 as complementary channels with overlap, not as substitutes.
- Confidence note — 2024 dispensing revenue figures for all three vendors are industry consensus estimates from Drug Channels Institute and IntuitionLabs analysis, not vendor-disclosed. None of the three publicly reports specialty pharmacy revenue separately from broader PBM/segment revenue. Manufacturers evaluating for partnership should request vendor-specific specialty-only metrics in RFP responses.
Editorial Firewall Disclosure
This comparison is written by the Rx Almanac editorial team using publicly available sources. None of the vendors named (CVS Specialty Pharmacy, Accredo/Evernorth, OptumRx Specialty Pharmacy) has sponsored, reviewed, or approved this content. Material public claims are cited inline where they need immediate context. Feedback and correction requests via the contact page; fact-based corrections are applied on verification, promotional edits are not accepted.
Related Wiki Vendors (Auto)
Auto-generated cross-references closing audit-surfaced link gaps. Vendors named in the prose above without inline links are listed here so the wiki graph is queryable.
Rx Almanac maintains a private source register for each article. Material public claims are cited inline; sourcing standards and correction policy are described in our methodology.
Related Articles
Analysis
340B TPA Comparison: Apexus vs Sentry Data Systems vs Macro Helix
Covered-entity 340B TPA comparison for Apexus, Sentry Data Systems, and Macro Helix, with manufacturer channel-risk implications.
Analysis
Cell and Gene Therapy Services Comparison: Orsini vs PANTHERx vs Onco360 vs Accredo vs CVS
This comparison supports a manufacturer-side CGT launch decision: which specialty-pharmacy and access partner can handle product-specific requirements around cryogenic handling, REMS, treatment-center coordination, payer access, hub orchestration, and long-term follow-up.
Analysis
Oncology Pharmacy Network Design: LDD Segmentation and Specialty Pharmacy Selection
This analysis gives manufacturer launch teams a practical oncology specialty pharmacy network design framework: when to use Onco360, when to include PBM-owned SPs, when health-system pharmacies matter, and when independent specialists or rare-disease pharmacies should be in the network.
Get more analysis like this
Weekly pharma vendor intel: new comparisons, market updates, and expert insights.
Found an inaccuracy? Tell us.
Suggest a correction